We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab.
- Authors
Pérez de Llano, Luis A.; Dacal Rivas, David; Cosío, Borja G.
- Abstract
Until recently, omalizumab was the only biologic approved by the regulatory agencies for treating asthma. Nowadays, more alternatives are available, and a significant proportion of severe asthma patients may qualify for both anti-IgE and anti-IL-5 therapies. In the meantime, the possibility of switching between monoclonal antibodies should make us more demanding about the categorization of clinical response in individual severe asthma patients.
- Subjects
ASTHMATICS; MONOCLONAL antibodies; PATIENT safety
- Publication
Allergy, 2020, Vol 75, Issue 4, p940
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.14035